Results 41 to 50 of about 16,194 (165)
Direct‐Acting Antiviral Therapy and Hepatocellular Carcinoma [PDF]
Clinical Liver Disease, 2021 Nicole E. Rich, Amit G. Singal
openaire +2 more sources
Direct-acting antivirals for RSV treatment, a review
Antiviral ResearchRespiratory syncytial virus (RSV) causes respiratory disease and complications in infants, the elderly and the immunocompromised. While three vaccines and two prophylactic monoclonal antibodies are now available, only one antiviral, ribavirin, is currently approved for treatment.
Brecht Bonneux +5 more
openaire +3 more sources
Journal of Virus Eradication, 2016 At present, routine antenatal hepatitis C virus (HCV) screening is not recommended in pregnant women who do not have known risk factors for infection. The main reason for this attitude has been the lack of effective treatment options to avoid mother-to ...
Karoline Aebi-Popp +4 more
doaj +1 more source
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Egyptian Liver Journal, 2020 Background Hepatitis C virus (HCV) infection is considered one of the main causes of chronic liver disease around the world. Liver biopsy has been believed to be the gold standard for the assessment of the degree of liver fibrosis.
Nancy Abdel Fattah Ahmed +3 more
doaj +1 more source
Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals [PDF]
Clinical and Molecular Hepatology, 2018 The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few side effects and no comorbidities in the general ...
Soon Young Ko, Won Hyeok Choe
doaj +1 more source
Virologic Tools for HCV Drug Resistance Testing
Viruses, 2015 Recent advances in molecular biology have led to the development of new antiviral drugs that target specific steps of the Hepatitis C Virus (HCV) lifecycle. These drugs, collectively termed direct-acting antivirals (DAAs), include non-structural (NS) HCV
Slim Fourati, Jean-Michel Pawlotsky
doaj +1 more source
Lipid Profile and Cardiovascular Risk Modification after Hepatitis C Virus Eradication
PathogensThe eradication of the hepatitis C virus (HCV) has revolutionized the hepatology paradigm, halting the progression of advanced liver disease in patients with chronic infection and reducing the risk of hepatocarcinoma.
Andrea Pascual-Oliver +4 more
doaj +1 more source
Revista do Instituto de Medicina Tropical de São Paulo, 2019 Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment ...
Marcos Mucenic +13 more
doaj +1 more source
Profile of alisporivir and its potential in the treatment of hepatitis C
Drug Design, Development and Therapy, 2013 Philippe A Gallay,1 Kai Lin21Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 2Permeon Biologics Inc, One Kendall Square, Cambridge, MA, USAAbstract: Two classes of hepatitis C antiviral agents currently exist,
Gallay PA, Lin K
doaj
Hepatitis C Treatment: A Review and Update
Southeastern European Medical Journal, 2017 Hepatitis C virus infection (HCV) infects approximately 185 million individuals worldwide. It is a leading cause of chronic liver disease and the primary reason for liver transplantation.
Jelena Jakab +4 more
doaj +1 more source